Accelerate development without compromising quality.

We move therapies forward faster: shareper development strategy, an accelerated end-to-end lifecycle through commercialization, and quality systems built for compliant execution at scale. The result is clearer decision-making, stronger regulatory readiness, and operating models designed for greater speed, productivity, and ownership from early development through submission and commercialization.

Schedule a Conversation

Development Strategy & Transformation

Make development decisions faster and build the organization to execute them.

We align portfolio priorities, clarify decision rights, and design operating models that support faster execution. The focus is practical: reduce friction, improve accountability, and create an organization that can move programs forward with greater speed and clarity.

Related Case Studies

Submission Acceleration

Acceleration of submissions while embedding long-term efficiency and accountability through a multi-year transformation.

Executive Alignment to Re-Shape Portfolio Priorities

Unification of executive leadership around data-driven decisions that balanced survival with long-term growth.

Building an Agile Launch Execution Team for Mission-Critical Launches

Development of an agile launch execution team that delivered two of the company's most successful launches while setting a benchmark for future execution.

End-to-End Development Acceleration

Find the critical path. Mobilize the organization around it.

IND-enabling studies through Phase 3 and submission, we identify the decisions, dependencies, and handoffs that determine development speed. We then work with cross-functional teams simplify execution, improve coordination, and apply technology where it can reduce cycle time and improve productivity.

Related Case Studies

54% Filing Time Acceleration

Halving the market approval filing timeline for a late-stage development organization.

CMC Module 3 Acceleration

Redesign of the E2E Module 3 submission process, achieving a 50-day cycle time reduction.

Reducing Trial Cycle Time by 6+ Months

Successful acceleration of development, reducing trial cycle times by over six months.

Clinical Quality Management Systems (GCP) Design & Optimization

Build quality systems that support both compliance and execution.

We design and optimize fit-for-purpose GCP quality systems, from diagnostics and governance through SOPs, eQMS implementation, remediation, and inspection readiness. The goal is a system that works in practice, scales with the pipeline, and is owned by your team.

Related Case Studies

eQMS Implementation for Rapidly Growing Biopharma

Implementation of a digital QMS that modernized quality operations and unlocked scalable compliance performance.

Global GCP Process & Procedure Realignment

Development of a global GCP QMS that transformed compliance from a burden into a strategic capability

Pre-Commercial Biotech QMS Establishment

Development of a pragmatic, inspection-ready QMS that enabled a client's first successful regulatory interactions.

Let’s talk about your specific challenge.

Whether the constraint is development speed, productivity, compliance, or internal capability, we define the change with you, execute beside your team, and build the capability to sustain it.

Schedule a Conversation

Perspectives for what’s next in drug development.

See how Scimitar approaches the decisions, systems, and capabilities that help teams move faster, improve productivity, and sustain progress.

Explore Our Perspectives

Accelerate development without compromising quality.

Explore Our Development Capabilities

Development Strategy & Transformation

End-to-End Development Acceleration

Clinical Quality Management Systems (GCP) Design & Optimization

From Our Perspectives

Decision Latency Is a Growth Strategy Problem: Redesigning Portfolio Governance for Speed and Discipline

AI Is Not Ready to Be the Decision-Maker, And Pretending Otherwise Is the Real Risk

Stop Asking Build vs. Buy: Most Biotechs Don't Have an AI Strategy at All

Let’s talk about your specific challenge.

Perspectives for what’s next in drug development.

Perspectives for what’s next in drug development.